Genmab

Update in progress

GMAB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Genmab A/S is a Copenhagen-based biotechnology company that develops antibody-based therapies for cancer and other diseases. It markets Epkinly and Tepkinly for relapsed/refractory DLBCL, large B-cell lymphoma, and follicular lymphoma; Tivdak for recurrent/metastatic cervical cancer; and Darzalex/Darzalex Faspro, Rybrevant, Tecvayli, Talvey, Kesimpta, and Tepezza. It is building numerous candidates (Epcoritamab, tisotumab vedotin, Acasunlimab, GEN programs) and collaborates with AbbVie, Pfizer, BioNTech, J&J, and others. Founded 1998, based in Copenhagen.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive